Evidence map›Paper›PMID 35472129›Full record

ArticleFEBS open bio2022

ETS transcription factor ELF3 (ESE-1) is a cell cycle regulator in benign and malignant prostate.

Leanne K Archer, Fiona M Frame, Hannah F Walker, Alastair P Droop, Georgina L K McDonald, Samuel Kucko, Daniel M Berney, Vincent M Mann, Matthew S Simms, Norman J Maitland

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Leanne K ArcherCancer Research Unit, Department of Biology, University of York, Heslington, UK.
Fiona M FrameCancer Research Unit, Department of Biology, University of York, Heslington, UK.ORCID 0000-0002-2377-1110
Hannah F WalkerCancer Research Unit, Department of Biology, University of York, Heslington, UK.
Alastair P DroopExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, UK.
Georgina L K McDonaldCancer Research Unit, Department of Biology, University of York, Heslington, UK.
Samuel KuckoCancer Research Unit, Department of Biology, University of York, Heslington, UK.
Daniel M BerneyDepartment of Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, UK.
Vincent M MannCancer Research Unit, Department of Biology, University of York, Heslington, UK.
Matthew S SimmsDepartment of Urology, Castle Hill Hospital, Cottingham, UK.
Norman J MaitlandCancer Research Unit, Department of Biology, University of York, Heslington, UK.
Yorkshire Cancer Research · GBCastle Hill Hospital · GBQueen Mary University of London · GBWellcome Sanger Institute · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to elucidate the role of ELF3, an ETS family member in normal prostate growth and prostate cancer. Silencing ELF3 in both benign prostate (BPH-1) and prostate cancer (PC3) cell lines resulted in decreased colony-forming ability, inhibition of cell migration and reduced cell viability due to cell cycle arrest, establishing ELF3 as a cell cycle regulator. Increased ELF3 expression in more advanced prostate tumours was shown by immunostaining of tissue microarrays and from analysis of gene expression and genetic alteration studies. This study indicates that ELF3 functions not only as a part of normal prostate epithelial growth but also as a potential oncogene in advanced prostate cancers.

Indexed as

DNA-Binding ProteinsProstateProstatic NeoplasmsProto-Oncogene Proteins c-etsTranscription FactorsCell CycleCell MovementHumansMaleDNA-Binding ProteinsELF3 protein, humanProto-Oncogene Proteins c-etsTranscription Factorscell cycleELF3patient samplesprostateprostate cancersiRNA

Identifiers

PMID35472129
PMCPMC9249341
OpenAlexW4224723143

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.